Cancer Chemotherapy and Pharmacology

, Volume 23, Issue 6, pp 337–340 | Cite as

CGP 6809 — A new nitrosoureido-sugar derivative with activity in human tumor xenografts

  • Heinz H. Fiebig
  • Karl H. Widmer
  • Bernd R. Winterhalter
  • Georg W. Löhr
Original Articles CGP 6809, Xenografts, Antitumor Activity


CGP 6809 [ethyl-6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)-α-d-glucofuranoside] is a new methylnitrosoureido-sugar derivative that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats [14]. We investigated the anti-tumour effect of CGP 6809 in ten selected, human tumour xenograft lines growing s. c. in nude mice. The p. o. administration of 125 mg/kg per day for 10–15 days was less toxic (lethality 12% in tumour-bearing nude mice) than the i. p. injection of 62.5 mg/kg per day (lethality 22%). The anti-tumour effect was similar for both application routes; two large bowel cancers responded to treatment with CGP 6809, rectal cancer CXF 158 showed a remission, and the rapidly growing, undifferentiated colonic cancer CXF 280 exhibited a transient no-change. Furthermore, remissions were observed in the epidermoid lung cancer LXF 322 and in thyroid cancer 117. Tumour progression was found in another epidermoid lung cancer and in three stomach cancers, one melanoma, and one soft tissure sarcoma. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.


Lung Cancer Melanoma Colonic Cancer Sarcoma Rectal Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bernacki RJ, Wilson GL, Mossmann BT, Angelino N, Kanter PM, Korytnyk W (1985) Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars. Cancer Res 45:695–702Google Scholar
  2. 2.
    Borisov VI (1977) Soviet antitumor preparations. In: Methods of development of new anticancer drugs. NCI Monograph 45. National Cancer Institute, Bethesda, pp 235–244Google Scholar
  3. 3.
    Carter SK (1981) Design of clinical trials with nitrosourea. In: Prestayko AW (ed), Nitrosourea. Academic Press, New York, pp 411–416Google Scholar
  4. 4.
    Eisenbrand G, Habs M, Zeller WJ, Fiebig H-H (1981) New-nitrosoureas therapeutic and long-term toxix effect of selected compounds in comparison to established drugs. In: Serrou B, Schein PS, Imbach JL (eds) Nitrosoureas in cancer treatment. INSERM Symposium 19. INSERM, Paris, pp 175–191Google Scholar
  5. 5.
    Fiebig HH, Löhr GW (1984) Wachstum menschlicher Malignome in der thymusaplastischen Nacktmaus. Med Welt 35: 52–58; 81–86Google Scholar
  6. 6.
    Fiebig HH, Schuchhardt C, Henß H, Fiedler L, Löhr GW (1984) Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 74:343–352Google Scholar
  7. 7.
    Fortmeyer HP, Bastert G (1981) Breeding and maintenance of nu/nu mice and rnu/rnu rats. In: Bastert G, Fortmeyer HP, Schmidt-Matthiesen H (eds) Thymus aplastic nude mice and rats in clinical oncology. G. Fischer Verlag, Stuttgart New York, pp 25–38Google Scholar
  8. 8.
    Franza BR, Oeschger NS, Oeschger MP, Schein PS (1980) Mutagenic activity of nitrosourea antitumor agents. J Natl Cancer Inst 65:149–154Google Scholar
  9. 9.
    Herr RR, Johnke H, Argondelis A (1967) The structure of streptozotocin. J Am Chem Soc 89:4808–4809Google Scholar
  10. 10.
    Johnston TP, McCaleb GS, Montgomery JA (1975) Synthesis and biologic evaluation of major metabolites of N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea. J Med Chem 18: 634–637Google Scholar
  11. 11.
    Montgomery JA (1976) Chemistry and structure-activity studies of the nitrosoureas. Cancer Treat Rep 60:651–664Google Scholar
  12. 12.
    Schein PS, O'Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, DeVita VT (1974) Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 34:993–1000Google Scholar
  13. 13.
    Schein PS, Panasci L, Woolley PV, Anderson T (1976) Pharmacology of chlorozotocin (NSC-178248), a new nitrosourea antitumor agent. Cancer Treat Rep 60:801–805Google Scholar
  14. 14.
    Schieweck K, Stanek J, Schmidt-Ruppin KH (1982) Effects of a new nitroso-ureido-sugar derivative, CGP 6809. Proceedings of the 13th International Cancer Congress, Seattle, p 385Google Scholar
  15. 15.
    Schieweck K, Stanek J, Schmidt-Ruppin KH (1988) Experimental antitumor activity of CGP 6809, a new sugar containing nitrosourea derivative. Cancer Chemother Pharmacol 23:341–346Google Scholar
  16. 16.
    Schmähl D (1981) Cancerogen wirkende Arzneimittel. In: Schmähl D (ed) Maligne Tumoren: Entstehung, Wachstum, Chemotherapie. Editio Cantor, Aulendorf, pp 203–220Google Scholar
  17. 17.
    Steel GG, Courtenay VD, Peckham MJ (1982) The immunesuppressed mouse as an alternative host for heterotransplantation. In: Fogh J (ed) The nude mouse in experimental and clinical research 2. Academic Press, New York, pp 207–227Google Scholar
  18. 18.
    Wiggans RG, Woolley PV, MacDonald JS, Smythe T, Ueno W, schein PS (1978) Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387–391Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Heinz H. Fiebig
    • 1
  • Karl H. Widmer
    • 1
  • Bernd R. Winterhalter
    • 1
  • Georg W. Löhr
    • 1
  1. 1.Department of Internal Medicine, Division of Hematology and OncologyUniversity of FreiburgFreiburg i. Br.Germany

Personalised recommendations